Biotech news, week of September 21, 2026

Machine summary Lawsuits have been filed against the makers of GLP-1 drugs over an alleged risk of sudden vision loss, according to multiple reports. One company said it monitors and reports safety information for all its medicines to the FDA.

1. USA Today said almost 1000 suits were filed in New Jersey alone over the past year.

Reported by fox26houston.com, wmtw.com, wdsu.com and whio.com.

Machine summary Key facts from the reports:

1. Syngenis Ventures, a wholly owned arm of Syngenis Labs, will own one-third of Gene S Dx, with the Perron Institute and Gene S founders collectively holding the remaining third, the reports state.
2. Dr Svetlana Baltic continues as chief executive and Dr Suzanna Lindsey-Temple as chief medical officer, with the technical, software, quality and regulatory team transferring into Gene S Dx, the reports state.

Reported by thewest.com.au and brisbanetimes.com.au.

• Syngenis Labs
• Gene S Dx
• Perron Institute
• Syngenis Ventures
• Gene S

The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

Reported by finanznachrichten.de and manilatimes.net.

• Theravance Biopharma
• Zymeworks Inc.

Machine summary An FDA advisory panel recommended that the agency approve Grail's Galleri multi-cancer blood test for people 50 and older, wcbe.org reported. The FDA is not required to follow its panels' advice, and Grail says its Galleri test is capable of finding up to 50 cancer types, according to wcbe.org. Wcbe.org reported no indication at the

1. wcbe.org reported that, per Grail, the Galleri test can identify as many as 50 cancer types, and most of those do not currently undergo routine screening.
2. wcbe.org reported that Phil Castle, who directs the Division of Cancer Prevention at the National Cancer Institute, informed the panel that Galleri's performance data were too premature to establish clinical benefit.

Reported by wcbe.org and local10.com.

• Grail
• National Cancer Institute
• Galleri
• multi-cancer blood test

Machine summary Experts say the NIH's total budget masks deeper disruptions in how research funding moves, according to reports. The Trump administration proposed a 41% cut to the NIH budget for 2026 and asked to restructure 27 institutes to eight, but Congress did neither, the reports state.

1. The National Institutes of Health wields a $47.5 billion budget, with more than 80% of its funds going out as grants, according to the reports.
2. According to the reports, the Trump administration put forward a proposal for 2026 to reduce the NIH budget by 41%, around $19.6 billion.
3. According to the reports, in its request the administration asked that 27 institutes be restructured into eight, with four cut entirely.
4. Congress did neither and maintained both the existing institutes and a budget on par with previous years' appropriations, the reports state.
5. The reports state that in fiscal year 2025, the NIH was about 44 days behind the average.

Reported by kmuw.org and news.wfsu.org.

• Congress
• National Institutes of Health

Reports ran between 00:45 and 01:45 UTC on Sep 25.

The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

Reported by nbcconnecticut.com and nbcwashington.com.